(INDIANAPOLIS, IN) - Indianapolis-based Eli Lilly and company has lost a legal battle over the patent for its ADHD drug Strattera.
A U.S. district court has ruled that Lilly's method-of-use patent is invalid, allowing for a generic version of the drug to enter the market in the near future.
Lilly Chairman and Chief Executive Officer John Lechleiter expects the loss of revenue to add to the challenges facing the company.
Have a question or comment about a news story? Send it to firstname.lastname@example.org